



Dr. Fred R. Hirsch, MD, PhD.

WCLC 2015 Congress President and IASLC Chief Executive Officer



Dr. Fred R. Hirsch, MD, PhD, has worked with clinical/ translational research in lung cancer for more than 25 years. His current interest is in biomarker developments for early detection and treatment of lung cancer. He is particularly studying markers related to molecular targeted therapies in order to understand the mechanisms of action and resistance of these new therapies, and to be able to select the patients who will benefit from such treatment. The biomarker studies include studies on lung cancer cell lines and tumor tissue from clinical cohorts. Dr. Hirsch's laboratory is currently studying biomarkers in multiple clinical trials performed in the US and

Europe both in lung and head and neck cancer.

Dr. Hirsch is the Co-Chair of the Southwest Oncology Group (SWOG) lung cancer translational science committee, and he has served as a member of the Thoracic Oncology Steering Committee for the US National Cancer Institute.

Dr. Hirsch has received several awards, including the prestigious IASLC Mary J. Matthews Award for his life time achievement in lung cancer translational science as well as the Japanese Lung Cancer Society's Merit Award and the Addario Lectureship Award.

Dr. Hirsch is a professor at the University Of Colorado, School Of Medicine in Denver, Colo., U.S, and is Associate Director for the University of Colorado Cancer Center. He is also adjunct professor at the Tongji University, Shanghai, China. He is the Chief Executive Officer of IASLC.

Dr. Hirsch holds a medical degree and doctorate from the University of Copenhagen, Denmark and a degree from the Copenhagen Business School.



Everett Vokes, MD

WCLC 2015 Congress Co-Chair



Everett E. Vokes, MD, the John Ulmann Professor and Chair, Department of Medicine at the University of Chicago, is an internationally renowned expert in the treatment of head and neck and lung cancer. Born in New York City, Dr. Vokes was educated in West Germany, receiving his medical degree from the University of Bonn Medical School. He served his residency in internal medicine at Ravenswood Hospital Medical Center in Chicago and at the University of Southern California in Los Angeles. He arrived at the University of Chicago as a hematology/oncology fellow in 1983 and was promoted to professor in 1995. For eleven years he served as chief of the Section of Hematology/Oncology, before his appointment as chair of the Department of Medicine in March 2009. In October 2009, Dr. Vokes was named interim dean of the Division of Biological Sciences and the Pritzker School of Medicine and interim vice president for medical affairs at the University of Chicago where he served for one year.

Dr. Vokes has spent a highly visible career in clinical and translational research involving head and neck and lung cancer, the interaction of chemotherapy and radiation, and lung cancer. His work has shown that intense treatment combining radiation and chemotherapy can bring locally advanced head and neck cancer under control and improve survival. His research in lung cancer is directed at identifying new active therapeutic agents, as well as the interaction of chemotherapy and radiation therapy.

In recognition of his outstanding work, Dr. Vokes has received many awards and has led many professional groups in the field of hematology/oncology. In 2008, he was one of two recipients of the new Translational Research Professorship from the American Society of Clinical Oncology and is a past recipient of a Francis L. Lederer Foundation grant for research on the malignancies of the upper aerodigestive tract.

Dr. Vokes is widely published with over 450 papers and 80 book chapters. He serves on numerous advisory committees and review panels and serves on the editorial boards of several journals, including the Journal of Clinical Oncology, Annals of Oncology, Clinical Lung Cancer, and Investigational New Drugs.



James Jett, MD


WCLC 2015 Congress Co-Chair



Dr. James Jett received his medical degree from the University of Missouri School of Medicine in Columbia, Mo., U.S. He undertook residency training in internal medicine at the Mayo Clinic in Rochester, Minn., where he also completed a fellowship in pulmonary medicine. Dr. Jett was Editor in Chief of Journal Thoracic Oncology from 2007-2012. Currently, he is Co-Editor of the Lung Cancer Section of UP-TO-DATE and is Professor of Medicine at National Jewish Health in Denver, Colorado. His research interests include biomarkers and screening for early detection of Lung Cancer.

Harvey I. Pass, MD

WCLC 2015 Congress Co-Chair



Dr. Pass is the Stephen E. Banner Professor of Thoracic Oncology, Division Chief of General Thoracic Surgery, and Vice Chair for Research for the Department of Cardiothoracic Surgery for the NYU Langone Medical Center. Dr. Pass is a surgeon scientist whose work focuses on the early detection, surgical management, and adjuvant therapy of thoracic malignancies.

From 1986-1996, Dr. Pass was Senior Investigator and Chief of the Division of Thoracic Oncology in the Surgery Branch of the National Cancer Institute, Bethesda, Maryland. He joined NYU Langone Medical Center in October 2005 from Wayne State University in Detroit where he was Professor of Surgery and Chief of Thoracic Oncology for nine years.

Dr. Pass has been continuously funded by the DOD, NCI, and the CDC among others since 1998 for the discovery and validation of blood-based biomarkers including osteopontin, soluble mesothelin related protein, and fibulin3. He has designed and published nine physician-initiated trials of novel therapies for lung cancer and mesothelioma among his 450 peer-reviewed publications. Dr. Pass has published 11 books including four editions of "Lung Cancer: Principles and Practice," "Malignant Mesothelioma: Advances in Pathogenesis," "Diagnosis and Translational Therapies," two editions of "100 Questions and Answers about Mesothelioma," and most recently "The IASLC Multidisciplinary Approach to Thoracic Oncology." He is Editor of Seminars in Thoracic and Cardiovascular Surgery and on the Editorial Board of Clinical Lung Cancer, Clinical Cancer Research, Current Treatment Options in Oncology, and Cancer Biomarkers.

Dr. Pass has been the recipient of the NIH Directors Award, the Wagner Medallion for contributions to the study of mesothelioma, the Pioneer Award from the Mesothelioma Foundation, and the Landon Award for Team Science from the American Association for Cancer Research.



Paul A. Bunn

Executive Director, 2003-2013; President, 1994-1997



Dr. Paul A. Bunn, Jr. is Distinguished Professor and the James Dudley Chair in Cancer Research in the Division of Medical Oncology at the University of Colorado Cancer Center of the Univ. of Colorado School of Medicine, where he has practiced and taught since 1984.

Dr. Bunn received his B.A. from Amherst College in Amherst, Mass., and received his M.D. from Weill Cornell Medical College in New York City. He completed an internship and residency at the University of California San Francisco and a fellowship in medical oncology at the National Cancer Institute (Bethesda) Program. He is board certified in internal medicine and medical oncology. Dr. Bunn served as the Head of the Division of Medical Oncology from 1984-1992 and as the Director of the Univ. of Colorado Cancer Center from 1986-2009. In the IASLC, Dr. Bunn served on the Board of Directors 1988-1994, President 1997-2000 and CEO 2004-2014. Dr. Bunn was the President of ASCO from 2002-2003.

The author of hundreds of articles, reviews and book chapters, Dr. Bunn's research is well known in the cancer world. He focuses primarily on novel therapies for lung cancer. Dr. Bunn has led numerous national and local trials regarding the treatment of lung cancer, and his findings are credited with setting standards in the treatment of the disease.

Dr. Bunn has researched new personalized therapies for lung cancer that cause fewer side effects than traditional, intravenous chemotherapy. He has also studied the genetics of the disease, seeking to learn how gene therapy could be used to combat the disease. He is currently the Principal Investigator on the Specialized Program in Research Excellence in Lung Cancer (SPORE) grant funded by the National Institutes of Health and the National Cancer Institute that aims to expand understanding about the biology of the disease, as well as to find new methods of diagnosis, prevention and treatment.

